Who Generates Higher Gross Profit? Grifols, S.A. or Taro Pharmaceutical Industries Ltd.

Grifols, S.A. leads in gross profit over Taro by a significant margin.

__timestampGrifols, S.A.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20141699214000580006000
Thursday, January 1, 20151930998000676585000
Friday, January 1, 20161912291000778966000
Sunday, January 1, 20172152011000671251000
Monday, January 1, 20182049560000463508000
Tuesday, January 1, 20192341232000445724000
Wednesday, January 1, 20202255165000399725000
Friday, January 1, 20211962596000296656000
Saturday, January 1, 20222231530000293122000
Sunday, January 1, 20232322701000268323000
Monday, January 1, 2024304979000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Grifols, S.A. vs. Taro Pharmaceutical Industries Ltd.

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Grifols, S.A. has consistently outperformed Taro Pharmaceutical Industries Ltd. in terms of gross profit. From 2014 to 2023, Grifols, S.A. maintained an average gross profit that was approximately four times higher than that of Taro. This Spanish multinational has shown remarkable resilience, with its gross profit peaking in 2019 at over 2.3 billion, while Taro's highest was just under 780 million in 2016. Despite fluctuations, Grifols, S.A. has demonstrated a steady upward trend, whereas Taro has faced a decline, particularly noticeable from 2017 onwards. As we look to the future, the data for 2024 remains incomplete, leaving room for speculation on whether Taro can close the gap or if Grifols will continue to dominate.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025